A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer

This multicentre, open-label, Phase Ib/II trial evaluated the insulin-like growth factor (IGF) 1/2 neutralising antibody xentuzumab plus enzalutamide in metastatic castrate-resistant prostate cancer (mCRPC). The trial included Phase Ib escalation and expansion parts and a randomised Phase II part ve...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of cancer Jg. 129; H. 6; S. 965 - 973
Hauptverfasser:	Macaulay, Valentine M, Lord, Simon, Hussain, Syed, Maroto, José Pablo, Jones, Robert Hugh, Climent, Miguel Ángel, Cook, Natalie, Lin, Chia-Chi, Wang, Shian-Shiang, Bianchini, Diletta, Bailey, Mark, Schlieker, Laura, Bogenrieder, Thomas, de Bono, Johann
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England Nature Publishing Group 05.10.2023
Schlagworte:	Antibodies, Neutralizing Antineoplastic Combined Chemotherapy Protocols - adverse effects Castration Humans Insulin-like growth factor I Insulin-like growth factors Male Metastases Metastasis mRNA Nitriles - therapeutic use Prostate cancer Prostate-specific antigen Prostatic Neoplasms, Castration-Resistant - pathology PTEN protein Treatment Outcome
ISSN:	0007-0920, 1532-1827, 1532-1827
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!